{
    "clinical_study": {
        "@rank": "124473", 
        "acronym": "ART", 
        "arm_group": {
            "arm_group_label": "Atorvastatin in Combination With Radiotherapy and Temozolomide", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to explore the efficacy and safety of Atorvastatin in\n      combination with multimodality therapy of concurrent radiotherapy plus temozolomide followed\n      by adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM).The\n      anticipated time on study treatment is until disease progression, and the target sample size\n      is 32 individuals."
        }, 
        "brief_title": "Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Glioblastoma Multiforme", 
        "condition_browse": {
            "mesh_term": "Glioblastoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven newly diagnosed Malignant Glioblastoma Multiforme or variants\n             (gliosarcoma, glioblastoma with oligodendroglial features, giant cell glioblastoma).\n\n          -  Age \u2265  18 years.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.\n\n          -  Patients must have an estimated life expectancy of at least 12 weeks.\n\n          -  No prior chemotherapy or radiotherapy.\n\n          -  Stable dose of steroid for  \u2265  14 days prior to registration.\n\n          -  Patients must have adequate bone marrow function (e.g., hemoglobin \u226510 g/dl, absolute\n             granulocyte count \u2265 1.5 x 109/L, and platelet count \u2265100 x 109/L.\n\n          -  Adequate liver function (SGPT, SGOT, and alkaline phosphatase \u2264 2.5 times upper\n             limits of normals (ULN) and total bilirubin \u22641.5 x ULN), and adequate renal function\n             (BUN or creatinine \u22641.5 X ULN) prior to starting therapy.\n\n          -  Paraffin embedded tumour sample available for study.\n\n          -  Patient consent must be obtained according to local Institutional requirements. The\n             patient must sign the consent form prior to registration.\n\n          -  Protocol treatment is to begin within 10 working days of patient registration.\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women; men and women of childbearing potential must agree to\n             practice an effective method of birth control. Women of childbearing potential must\n             have a negative pregnancy test performed within 14 days prior to registration.\n\n          -  Concurrent treatment with other experimental drugs or anticancer therapy.\n\n          -  Patients with a history of other malignancies, except: adequately treated\n             non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other\n             solid tumours curatively treated with no evidence of disease for > 5 years.\n\n          -  Prior radiotherapy or systemic cytotoxic chemotherapy .\n\n          -  Severe, active co-morbidity, defined as follows: Acute bacterial or fungal infection\n             requiring intravenous antibiotics at the time of registration, Chronic obstructive\n             pulmonary disease exacerbation or other respiratory illness requiring hospitalization\n             or oxygen, Hepatic insufficiency  or Active liver disease resulting in clinical\n             jaundice and/or coagulation defects, Acquired immune deficiency syndrome (AIDS) ,\n             Significant neurologic or psychiatric disorder which would impair the ability to\n             obtain informed consent, Active uncontrolled or serious infection, active peptic\n             ulcer disease, Any medical condition which could interfere with oral medication\n             intake (e.g., frequent vomiting, partial bowel obstruction), Myocardial infarction\n             within 6 months prior to registration, Congestive heart failure, unstable angina,\n             active cardiomyopathy, cardiac arrhythmia, Skeletal muscle disease and other related\n             reticule-endothelial diseases.\n\n          -  Patients with known hypersensitivity to the study drugs or their components."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029573", 
            "org_study_id": "KFMC-CNS-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Atorvastatin in Combination With Radiotherapy and Temozolomide", 
                "description": "80 mg po  daily until disease progression or unacceptable toxicity. (starting dose of 40 mg po daily for the first 21 days)", 
                "intervention_name": "Atorvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Atorvastatin in Combination With Radiotherapy and Temozolomide", 
                "description": "75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy", 
                "intervention_name": "Temozolomide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Atorvastatin in Combination With Radiotherapy and Temozolomide", 
                "description": "60 Gy in 30 fractions", 
                "intervention_name": "Radiotherapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Temozolomide", 
                "Dacarbazine", 
                "Atorvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phase II", 
            "Atorvastatin", 
            "Temozolomide", 
            "Radiotherapy", 
            "Glioblastoma Multiforme (GBM)"
        ], 
        "lastchanged_date": "March 7, 2014", 
        "location": {
            "contact": {
                "email": "aaltwairqi@kfmc.med.sa", 
                "last_name": "Abdullah K. Altwairgi, MD", 
                "phone": "+966 1 288 9999", 
                "phone_ext": "11796"
            }, 
            "contact_backup": {
                "email": "hmunshi@kfmc.med.sa", 
                "last_name": "HumariyaI H. Munshi", 
                "phone": "+966 1 288 9999", 
                "phone_ext": "14029"
            }, 
            "facility": {
                "address": {
                    "city": "Riyadh", 
                    "country": "Saudi Arabia", 
                    "zip": "11525"
                }, 
                "name": "King Fahad Medical City"
            }, 
            "investigator": [
                {
                    "last_name": "Abdullah K. Altwairgi, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Rasha Saleh, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Eyad Alsaeed, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ali Balbaid, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Hussain Alhussain, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Fouad Alnajjar", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mohamed Mubasher", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Waleed Alghareeb", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ali Alfakeeh", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Saudi Arabia"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma", 
        "overall_contact": {
            "email": "aaltwairqi@kfmc.med.sa", 
            "last_name": "Abdullah K. Altwairgi, MD", 
            "phone": "+966 1 288 9999", 
            "phone_ext": "11796"
        }, 
        "overall_contact_backup": {
            "email": "hmunshi@kfmc.med.sa", 
            "last_name": "Humariya H. Munshi", 
            "phone": "+966 1 288 9999", 
            "phone_ext": "14029"
        }, 
        "overall_official": {
            "affiliation": "King Fahad Medical City", 
            "last_name": "Abdullah K. Altwairgi, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Saudi Arabia: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All efficacy determinations will be based on the Response Assessment in Neuro-Oncology (RANO) response criteria (Wen 2010)", 
            "measure": "Progression free survival at 6 months (PFS-6)", 
            "safety_issue": "No", 
            "time_frame": "up to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029573"
        }, 
        "responsible_party": {
            "investigator_affiliation": "King Fahad Medical City", 
            "investigator_full_name": "Abdullah Khalaf Altwairgi", 
            "investigator_title": "Medical Oncologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression free survival defined as the time the patient enters the study until first progression or death whichever occurs first", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 2-3 years"
            }, 
            {
                "description": "Overall Survival defined as the time the patient enters the study to the date of death due to any cause.", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2-3 years"
            }, 
            {
                "description": "The assessment of safety will be based on the frequency of Adverse Events graded (grade 3+) according to the Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) version 4.0 scoring system.", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2-3 years"
            }
        ], 
        "source": "King Fahad Medical City", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "King Fahad Medical City", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}